Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

The present invention is directed to combinations of a β-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of β-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.

##STR00001##

Compounds of formula I are provided herein, as well as the use of these compounds for controlling invertebrate pests. Plant propagation material and agricultural and veterinary compositions including these compounds are also provided. Compounds for use as intermediate compounds in the preparation of the compounds of formula I are also described.

The invention relates to an oil-in-water dispersion comprising coniferous resin acids, its preparation and use as an antimicrobial and anti-inflammatory agent in medical and non-medical products. The invention also relates to a pharmaceutical product comprising the oil-in-water dispersion.

The dual microbial preparation contains the microscopic oomycete Pythium oligandrum and components of a physiological microbiome. The microscopic oomycete Pythium oligandrum and the physiological microbiome component are present in the dual preparation in a form which facilitates their germination, subsequent propagation and colonization of the target tissues. The microscopic oomycete Pythium oligandrum is incorporated in a quantity of 10.sup.3 to 10.sup.7 CFU (colony forming units), with 10.sup.4 to 10.sup.5 CFU per one cycle of application preferably. The physiological microbiome component contains 5×10.sup.6 to 5×10.sup.10 CFU, with 5×10.sup.7 to 5×10.sup.9 per one cycle of application preferably. The fermented substrate found in the Pythium oligandrum oomycete is the source of nutrients for both microbial components. The dual microbial preparation also contains at least one auxiliary substance from a group including a desiccant, components of a buffer system, an anti-caking substance and an agent for the creation of a physiological osmotic environment. The physiological microbiome component is a component of the human microbiome, one of the microbes of the green complex, such as the Capnocytophaga sputigena bacterium, or one of the components of the healthy skin microbiome, such as the Staphyloccocus epidermidis bacterium, or one of the components of the healthy vaginal microbiome, such as the peroxide producing Lactobacillus crispatus. Either the microscopic oomycete Pythium oligandrum or the physiological microbiome component is present in the dual microbial preparation in the form of inactivated cells, cell extracts or isolated cell fractionation. The microbial activator for the Pythium oligandrum oomycete is a yeast autolysate in a quantity of 0.1% to 10% weight of the total quantity of dual microbial preparation. The auxiliary substances are regulated in a way which allows for application in the form of an ointment, cream, oil or suppository or in the form of a liquid aqueous preparation.

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula:

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

Provided herein are intermediates and processes useful for facile synthesis of compounds of formula (I):

##STR00001##

or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Q, P.sup.1 and P.sup.2 are as defined in this disclosure.

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and antiinflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and antiinflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.

Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients.